Deep sequencing analysis of M184V/I mutation at the switch and at the time of virological failure of boosted protease inhibitor plus lamivudine or boosted protease inhibitor maintenance strategy (substudy of the ANRS-MOBIDIP trial).

doi:10.1093/jac/dkab002

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Deep sequencing analysis of M184V/I mutation at the switch and at the time of virological failure of boosted protease inhibitor plus lamivudine or boosted protease inhibitor maintenance strategy (substudy of the ANRS-MOBIDIP trial).

The Journal of antimicrobial chemotherapy - 13 Apr 2021

Delaugerre Constance, Nere Marie-Laure, Eymard-Duvernay Sabrina, Armero Alix, Ciaffi Laura, Koulla-Shiro Sinata, Sawadogo Adrien, Ngom Gueye Ndaye Fatou, Ndour Cheik Tidiane, Mpoudi Ngolle Mireille, Amara Ali, Chaix Marie-Laure, Reynes Jacques

Abstract excerpt

BACKGROUND: The ANRS12286/MOBIDIP trial showed that boosted protease inhibitor (bPI) plus lamivudine dual therapy was superior to bPI monotherapy as maintenance treatment in subjects with a history of M184V mutation. OBJECTIVES: We aimed to deep analyse the detection of M184V/I variants at time of switch and at the time of virological failure (VF). METHODS: Ultra-deep sequencing (UDS) was performed on proviral...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to High-Throughput Nucleotide Sequencing

Share to HIV-1

Share to HIV Infections

Share to Lamivudine

Share to Protease Inhibitors

Share to Viral Load

Source

Open in PubMed

Identifiers

PMID: 33624081
DOI: 10.1093/jac/dkab002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Deep sequencing analysis of M184V/I mutation at the switch and at the time of virological failure of boosted protease inhibitor plus lamivudine or boosted protease inhibitor maintenance strategy (substudy of the ANRS-MOBIDIP trial).PMID 33624081Read ↗

Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort StudySemantic proximity Read ↗

HIV-1 DNA ultra-deep sequencing analysis at initiation of the dual therapy dolutegravir + lamivudine in the maintenance DOLULAM pilot study.Semantic proximity Read ↗

Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced PatientsSemantic proximity Read ↗

The RT M184V resistance mutation clearance in the reservoir is mainly related to CD4 nadir and viral load zenith independently of therapeutic regimen type.Semantic proximity Read ↗

Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing.Semantic proximity Read ↗

Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients.Semantic proximity Read ↗

The impact of the M184V resistance mutation on treatment outcomes in patients with HIV infection: a systematic review and meta-analysis.Semantic proximity Read ↗

Differential detection of M184V/I between plasma historical HIV genotypes and HIV proviral DNA from PBMCs.Semantic proximity Read ↗

Impact of Proviral-DNA M184V/I on 96-Week Outcomes of DTG/3TC Maintenance Therapy: Results From the VOLVER Clinical Trial.Semantic proximity Read ↗

Treatment Management Challenges in Naïve and Experienced HIV-1-Infected Individuals Carrying the M184V Mutation.Semantic proximity Read ↗

Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation.Semantic proximity Read ↗

Treatment Management Challenges in Naïve and Experienced HIV-1-Infected Individuals Carrying the M184V MutationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.